What Gastrolina Treats: Main Uses and Benefits

Symptomatic support is considered relevant to help manage symptoms associated with acute or episodic changes. Gastrolina is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability when symptoms create noticeable physiological strain. It is applied in addressing situations involving certain distressing symptoms that create temporary functional strain in daily life.

Common scenarios involve supporting the management of symptom clusters that may become intense or disruptive. This medicine is often applied during phases when symptoms become more noticeable, offering supportive relief when short-term symptomatic assistance is needed.

“It assists with short-term symptomatic assistance, supporting patients during difficult episodes to help maintain functional stability.”

It is commonly used across conditions presenting with episodic or fluctuating manifestations. It contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Symptomatic Support for Episodic Manifestations

Regulatory References

1. NIH MedlinePlus overview of pain and symptom types

Who can and cannot use Gastrolina

The use of Gastrolina (Hyoscine Butylbromide / Sodium Metamizole) is strictly defined by mandatory population eligibility rules documented in global regulatory sources. These restrictions are based on the risk profiles of the two active components.

---

Absolute Contraindications

Gastrolina is contraindicated in specific populations to prevent serious health risks. These include individuals with a history of impaired blood cell production (haematopoiesis), a previous episode of agranulocytosis from Metamizole, or known hypersensitivity to either active ingredient. Use is also strictly prohibited in patients with certain gastrointestinal obstructions (e.g., paralytic ileus, megacolon), untreated narrow-angle glaucoma, or prostatic hypertrophy with urinary retention.

---

Eligibility Restrictions

• Geographic: Populations in jurisdictions where Sodium Metamizole has been banned or withdrawn for human use (e.g., the United States and the United Kingdom) are ineligible.
• Age: Fixed-dose tablets are not recommended for children under 15 years and are contraindicated in infants younger than 3 months or those under 5 kg. Older adults may require caution and a reduced dose.
• Physiological State: Use is contraindicated during the third trimester of pregnancy and is not recommended while breastfeeding due to metabolite excretion.
• Organ Function: Patients with severe hepatic impairment or severe renal impairment are generally contraindicated.

Interactions with other medicines and products

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Anticholinergic agents, dopamine antagonists, beta-adrenergic agents, general CYP substrates, NSAIDs, immunosuppressants.
Specific interacting medicines (if explicitly listed)	Acetylsalicylic Acid (Aspirin), Ciclosporin, Methotrexate, Chlorpromazine, Metoclopramide, Anticoagulants (parenteral route), Tricyclic Antidepressants.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (Enzyme Induction): The Metamizole component is a documented moderate to strong inducer of CYP3A4, CYP2B6, and CYP2C19. Pharmacodynamic Interaction: Potentiation of anticholinergic effects and antagonism of prokinetic agents.
Timing-based interaction rules (if applicable)	Acetylsalicylic Acid (Antiplatelet): Administration may require time separation to avoid inhibiting the antiplatelet effect.
Population-specific interaction notes (if applicable)	The Metamizole component is contraindicated during the last trimester of pregnancy and breastfeeding.
Interaction-related restrictions	Co-administration is restricted with other anticholinergic agents. Intramuscular administration of the injectable form is restricted in patients receiving anticoagulants.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Classification/Basis
Interaction severity classification (as defined in official documents)	Formal Contraindication (with specific co-administrations/routes); Use-with-Caution (for metabolic interactions); Risk of Additive Effect (for pharmacodynamic interactions).
Regulatory basis (EMA / FDA / etc.)	Summaries of Product Characteristics (SmPC) / Public Assessment Reports / Official Regulatory Monographs.
Interaction-context constraints (as defined in official documents)	Must consider the dual constraints of the Anticholinergic (Hyoscine) component and the Analgesic/Metabolic (Metamizole) component.

---

Resulting Interaction Structure

The regulatory documentation defines this product's interaction structure based on its dual active components: the Metamizole component primarily establishes constraints via pharmacokinetic (enzyme induction) pathways, leading to reduced exposure for sensitive substrate drugs like Ciclosporin. The Hyoscine Butylbromide component primarily establishes constraints via pharmacodynamic (additive or antagonistic) effects, resulting in the potentiation of other anticholinergic agents and potential antagonism of Metoclopramide. The label restricts co-administration of the injectable form via the intramuscular route with anticoagulants and specifies that the combination with Aspirin must be managed to avoid inhibiting its antiplatelet effect.

How Gastrolina Works: A Mechanistic Overview

Gastrolina exerts its pharmacological effect through a dual mechanism involving antagonism at Dopamine D2 receptors in both the central and peripheral nervous systems. Centrally, the drug acts in the Chemoreceptor Trigger Zone (CTZ), where D2 receptor blockade modifies a key brain pathway, resulting in a decreased sensitivity of the central signaling area to circulating chemical stimuli.

Peripherally, the mechanism extends to the enteric nervous system and gastrointestinal musculature. Here, D2 antagonism is combined with enhanced activity of the messenger acetylcholine. This simultaneous influence on the muscular and neural components of the gut alters propulsive muscle tone. The resulting physiological modulation includes altered gastric emptying kinetics and modified contractile patterns throughout the upper digestive tract. The overall mechanism engages cascades that adjust signaling dynamics to influence the neuro-muscular activity of involuntary gastrointestinal movement and afferent signaling.

Gastrolina is administered through two distinct delivery methods: the oral route via a tablet formulation and the parenteral route via a solution for injection. This choice defines whether the medicine is used in an outpatient or acute care setting. For the oral tablet, the dose of the antispasmodic component (Hyoscine Butylbromide) is typically 10 mg to 20 mg per single administration, a regimen that may be repeated up to four times daily as needed. The tablet form requires specific handling and must be swallowed whole with water, ensuring it is not crushed or broken.

The parenteral solution is generally administered as a 20 mg single dose of the antispasmodic component. Approved routes include intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection. When utilizing the intravenous route, the injection is required to be administered slowly. Overall administration is governed by a strict limit: the total daily dose of the antispasmodic component should not exceed 100 mg in a 24-hour period. The combination also contains the analgesic Sodium Metamizole, which is limited to a maximum total of 4,000 mg per day. A further constraint on use is the Course Duration Constraint, which reserves Gastrolina strictly for short-term, acute symptomatic relief and explicitly forbids continuous daily administration or extended therapy without medical review. For children aged 6 to 12 years, a defined oral regimen of 10 mg three times daily is documented for the antispasmodic component.

Research Evidence / Overview of Studies for Gastrolina

---

Evidence for Use in Acute Visceral Pain and Colic

Research examined short-term symptom changes for acute visceral pain, such as renal colic, utilizing Randomized Controlled Trials (RCTs) and comparative studies. These studies were observed in adults presenting with severe pain caused by smooth muscle spasm. Researchers monitored outcomes related to physical discomfort, including changes in pain intensity using standardized scales, and studies monitored the Need for Rescue Analgesia documented during the acute event.

Studies focused on episodes where symptoms become more noticeable, reporting measurements of pain intensity changes in the immediate, acute setting. Findings describe patterns observed in the studies related to how patients reported their experience during these short observational periods. Evidence contributes to understanding symptom patterns over defined time intervals, typically ranging from a single dose up to 48 hours.

It is important to note that direct, high-quality evidence for the specific fixed-dose combination has been limited. Evidence consistency varies across studies, and many findings rely on research that was evaluated in the components (the antispasmodic and the analgesic) separately, or in combinations that use a different analgesic. Research describes that the follow-up durations were limited, meaning that long-term outcomes following multiple acute episodes are not well characterized.

---

Evidence for Use in Primary Dysmenorrhea

The combination was observed in research that explored outcomes related to physical discomfort associated with Primary Dysmenorrhea (menstrual cramps). Research explored short-term symptom changes, primarily through Randomized Controlled Trials (RCTs), where dual-action formulations containing an antispasmodic plus an analgesic was evaluated in women of reproductive age. Study outcomes examined included the intensity of Pain and Cramping and the impact on Daily Functioning or Activity Level, such as the ability to perform daily chores.

Research describes how symptoms evolved in the observed populations during periods of increased symptom activity. Findings describe patterns observed in the studies related to changes in pain and cramping measured within a few hours of dosing and across the typical short treatment cycle for dysmenorrhea episodes.

Evidence is limited for this specific combination in dysmenorrhea. Many RCTs supporting the dual-action approach used an analogous formulation where the antispasmodic (Hyoscine Butylbromide) was associated with a different analgesic, such as paracetamol. The evidence base includes RCTs of other fixed-dose combinations with dual components. Follow-up durations were limited, meaning that the research provides context but not individual predictions about long-term consistency across multiple menstrual cycles.

---

Long-Term Studies and Extended Follow-up

Existing research primarily focuses on acute or episodic changes, observing responses over defined time intervals in settings with varying symptom burdens. For conditions associated with acute or disruptive episodes, studies monitored changes in outcomes related to physical discomfort over very short-term periods, often a single administration or up to two days.

Long-term effects are not fully established for this combination because research generally stops after the resolution of the acute event. There is limited information for long-term outcomes or the durability of observed responses. Existing studies provide limited insight into the long-term management of conditions characterized by fluctuating or episodic manifestations.

---

Evidence in Specific Populations

Research exploring temporary physiological imbalance has explored the use of the medicine’s components in various populations. Studies monitored groups where symptoms may vary in intensity.

However, data for certain groups remain insufficient. For instance, evidence is limited for the use of the combination in children or older adults, meaning that the results apply only to the populations studied in the core clinical trials. Subgroup findings are uncertain for pregnant populations or those with significant comorbid conditions, as these groups are generally excluded from initial pivotal trials.

---

What is Still Uncertain About Gastrolina Research

Evidence highlights what is known—and what is still uncertain—about the medicine’s research base. One key area is that comparative evidence is lacking for the specific fixed-dose combination when measured directly against its individual monotherapy components in large-scale trials.

Furthermore, evidence consistency varies across studies, and the interpretation of findings requires careful consideration, as data on the antispasmodic component alone has been mixed in certain severe colic cases. The limited follow-up durations mean that long-term effects are not fully established, and long-term outcomes are not well characterized. Research contributes to the broader evidence landscape. Findings describe group patterns, not personal outcomes.

Key Studies & References

1. Assessment report - Referral under Article 31 of Directive 2001/83/EC metamizole-containing medicinal products INN
2. Hyoscine N-Butylbromide: A Review of its Use in the Management of Abdominal Pain and Functional Bowel Disorders
3. The evidence for using hyoscine N-butylbromide (Buscopan) in ureteric obstruction
4. Real-world effects of hyoscine butylbromide combined with paracetamol in women with dysmenorrhea: a patient survey

Common questions about Gastrolina (FAQ)

Q: Is it normal to feel slightly dizzy after starting Gastrolina?

According to official product information, dizziness is one of the commonly documented side effects associated with the Hyoscine Butylbromide component of the medicine. This is a recognized adverse reaction listed in regulatory documents.

---

Q: Can Gastrolina be taken with common over-the-counter pain relievers?

Regulatory documents indicate that Gastrolina has documented interactions with certain classes of medicines, including NSAIDs and products containing Acetylsalicylic Acid (Aspirin), which are common pain relievers. Official information notes that these interactions may require careful consideration, such as time separation of administration, based on the complete list of known interactions.

---

Q: What is the difference between Gastrolina and other similar stomach medicines?

Gastrolina is officially classified as a Combined Analgesic-Spasmolytic Agent. This means it contains two active ingredients: one to relieve pain (analgesic) and one to relax the smooth muscle (spasmolytic). This dual-action approach distinguishes it from single-component treatments like antacids or some monotherapy pain relievers.

---

Q: Why do some people confuse Gastrolina with supplements?

Gastrolina is officially classified as a Fixed-Dose Combination Medicinal Product, which means it is regulated as a drug by government health authorities. This classification is based on its synthetic chemical structure and defined pharmacological components. Supplements follow different regulatory pathways than prescription medicinal products.

---

Q: What kind of studies support the use of Gastrolina?

Studies and official information indicate that the medicine's use is supported by clinical research, including Randomized Controlled Trials (RCTs). This research has primarily focused on evaluating the medicine's effect on short-term symptom changes in acute pain and colic.

---

Q: Do researchers know exactly how Gastrolina works inside the body?

The mechanism for the antispasmodic component (Hyoscine Butylbromide) is described as well-defined in official documents. However, regulatory documents note that the precise mechanism of the analgesic component (Sodium Metamizole) is not fully understood and is still an area of scientific study.

---

Q: Is Gastrolina for short-term use only?

According to the official product information, Gastrolina is strictly intended for short-term, acute symptomatic relief only. It is explicitly not recommended for continuous daily administration or for use over extended periods without medical investigation of the cause.

---

Q: How quickly does Gastrolina usually start working?

Official regulatory documents indicate that a noticeable pain-relieving effect from the oral tablet formulation is generally expected to begin 30 to 60 minutes after the dose is taken.

---

Q: What should I look out for when taking Gastrolina?

Regulatory sources highlight the need for vigilance concerning symptoms of serious adverse reactions, such as those related to agranulocytosis (a severe drop in white blood cells). These warnings note to observe for signs like unexplained fever or a sore throat. The regulatory documents also draw attention to signs of a severe allergic reaction (anaphylaxis).

---

Q: Will Gastrolina affect my ability to drive?

Official product information notes that the medicine may cause visual disturbances or dizziness in some individuals. Due to these potential effects, regulatory cautions are in place regarding avoiding driving or operating machinery if these side effects are experienced.

---

Q: Can you take Gastrolina if you have kidney problems?

Official documentation indicates that the medicine is contraindicated (not recommended for use) in patients with severe renal impairment (severe kidney problems). For individuals with non-severe kidney impairment, regulatory notes advise using the medicine with caution and potentially using a lower dose.

---

Q: What is the longest period of time people typically take Gastrolina?

Regulatory constraints require the medicine to be used for short-term, acute relief only. The official product information specifies that the medicine is explicitly not intended for continuous daily or extended use and must adhere to the defined acute-use period.

---

Q: Is there a generic version of Gastrolina available?

The two active medicinal ingredients in Gastrolina, Hyoscine Butylbromide and Sodium Metamizole, are established generic substances. The combination product itself may be available under different brand names, depending on the country or region of use.

---

Q: Are there different strengths of Gastrolina tablets?

Gastrolina is available in different pharmaceutical forms, including oral tablets and a solution for injection. The active ingredients are contained in different doses across these various formulations to address acute pain. For example, the analgesic component is often available in a 500 mg tablet strength.

---

Q: Does alcohol increase the side effects of Gastrolina?

Official patient information generally advises caution regarding alcohol consumption while using the medicine. This is because alcohol may worsen side effects such as dizziness or drowsiness associated with the medicine's components and their effects on the central nervous system.

---

Q: Are headaches a known side effect of Gastrolina?

Yes, headache is an adverse reaction that has been officially documented and reported in regulatory documents. This side effect is associated with the analgesic component (Sodium Metamizole) of the medicine.

---

Q: Does Gastrolina affect birth control pills?

Regulatory documents advise caution because one of the active components is a documented inducer of certain CYP liver enzymes. This mechanism has the potential to affect the effectiveness of other medicines, including hormonal contraceptives, by changing their plasma levels.

---

Q: Can Gastrolina be used by patients with heart conditions?

Official product information states that the medicine is contraindicated (not recommended for use) in patients with specific severe cardiac conditions, such as tachycardia, angina, and cardiac failure. For other heart conditions, caution is generally advised by regulatory authorities.

---

Q: Are there any known long-term side effects of Gastrolina?

Research and regulatory assessment reports note that long-term effects are not fully established because the medicine is strictly intended for short-term, acute relief. However, serious reactions like Agranulocytosis are officially documented to occur at any time during treatment, which is a consideration for any duration of use.

---

Q: What happens during the clinical trials for Gastrolina?

Clinical trials are primarily designed to evaluate the medicine's efficacy (its ability to reduce pain and spasm) and overall safety in defined patient groups. Researchers monitor specific endpoints, such as changes in pain intensity, over the short-term periods of the acute episode.

Gastrolina should be stored at controlled room temperature (typically 15 C to 25 C), away from excessive heat, moisture, and direct light. Storing medication in a bathroom cabinet should be avoided due to humidity. Always keep the medicine in its original container and ensure it is kept out of the sight and reach of children and pets.

For disposal of expired or unused Gastrolina, do not flush it down a toilet or pour it down a sink unless specifically instructed by the manufacturer or a regulator like the FDA. The preferred method is to utilize a drug take-back program or a permanent disposal kiosk often located at pharmacies or police stations.

If a take-back option is unavailable, you can dispose of the medication in the household trash. First, remove the drug from its original container and mix it with an undesirable substance, such as used coffee grounds, dirt, or cat litter. Place the mixture in a sealed bag or container before discarding it in the trash. Always scratch out or remove personal information from the empty container.